Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

38 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Estrogen receptor dynamics in diverse patient-derived luminal breast cancer xenografts

ABSTRACT: Primary breast cancer xenografts Two primary xenografts with different treatments

ORGANISM(S): Homo sapiens

SUBMITTER: peter kabos

PROVIDER: E-GEOD-36075 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Estrogen receptor dynamics in diverse patient-derived luminal breast cancer xenografts

Project description:Primary breast cancer xenografts

2013-02-24 | GSE36075 | GEO

Defining CD4 T Cell Memory by the Epigenetic Landscape of CpG DNA Methylation [Affymetrix]

Project description:Memory T cells are primed for rapid responses to antigen; however, the molecular mechanisms responsible for priming remain incompletely defined. CpG methylation in promoters is an epigenetic modification, which regulates gene transcription. Using targeted bisulfite sequencing, we examined methylation of 2100 genes (56,000 CpG) mapped by deep sequencing to T cell activation in human naïve and memory CD4 T cells. 466 CpGs (132 genes) displayed differential methylation between naïve and memory cells. 21 genes exhibited both differential methylation and gene expression before activation, linking promoter DNA methylation states to gene regulation; 6 genes encode proteins closely studied in T cells while 15 genes represent novel targets for further study. 39 genes exhibited reduced methylation in memory cells coupled with increased gene expression with activation compared to naïve cells, revealing specific genes more rapidly expressed in memory compared to naïve cells and potentially regulated by DNA methylation. These findings define a DNA methylation signature unique to memory CD4 T cells and correlated with activation-induced gene expression. transcriptome of primary human naïve and memory CD4 T cells at rest and 48 hours post-activation.

2015-01-20 | E-GEOD-58684 | biostudies-arrayexpress

scRNA-seq analysis of patient-derived luminal breast cancer xenografts

Project description:Primary breast cancer xenografts

2022-08-12 | GSE136260 | GEO

ChIPseq analysis of patient-derived luminal breast cancer xenografts with progestins

Project description:Primary breast cancer xenografts

2017-01-04 | GSE93108 | GEO

RNAseq analysis of patient-derived luminal breast cancer xenografts treated with progestins

Project description:Primary breast cancer xenografts

2017-01-04 | GSE93057 | GEO

Estrogen receptor dynamics in diverse patient-derived luminal breast cancer xenografts

Project description:Primary breast cancer xenografts Two primary xenografts with different treatments

| S-ECPF-GEOD-36075 | biostudies-other

Expression data from patient and primary xenografts esophageal tumour samples

Project description:Microarrays were used to assess differences between 1) human tumours that did and did not engraft, 2) human tumours and their matched primary xenografts, 3) early and late passage primary xenografts and 4) small and large primary xenografts for a series of esophageal patient and primary xenograft tumours

2015-01-11 | GSE58870 | GEO

Patient-derived luminal breast cancer xenografts with progestins

Project description:Patient-derived luminal breast cancer xenografts with progestins

| PRJNA360064 | ENA

A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-derived Human Breast Cancer Xenografts

Project description:Translational breast cancer research is hampered by difficulties in obtaining and studying primary human breast tissue, and by the lack of in vivo preclinical models that reflect patient tumor biology accurately. In an effort to overcome these limitations, we propagated a cohort of human breast tumors grown in the mammary fat pad of SCID/Beige and NOD/SCID/IL2?-receptor null (NSG) two relatively new immunocompromised mouse models, under a series of transplant conditions. Both models yielded stably transplantable xenografts relatively high rates compared with previously available immunocompromised mice. Xenograft lines were established directly from breast cancer patient samples, without intervening culture in vitro, using the epithelium-free mammary fat pad as the transplantation site. Of the conditions tested, xenograft take rate was highest in the presence of a low-dose estradiol pellet. Overall, 35 stably transplantable xenograft lines representing 27 patients were established, using pre-treatment, mid-treatment, and/or post-treatment samples. Most patients yielding xenografts were “triple-negative” (ER-PR-HER2-) (n=21). However, we were able to establish lines from three ER-PR-HER2+ patients, one ER+PR-HER2-, one ER+PR+HER2- and one “triple-positive” (ER+PR+HER2+) patient. Serially passaged xenografts show biological consistency with the tumor of origin at the histopathology level, and remarkable stability across multiple transplant generations at the genomic, transcriptomic, and proteomic levels. Of the 27 patients represented, xenografts derived from 13 patients showed metastasis to the mouse lung. These models thus serve as a renewable, quality-controlled tissue resource, and should prove useful for preclinical evaluation of experimental therapeutics. reference x sample

2013-06-25 | E-GEOD-34412 | biostudies-arrayexpress

Expression data for childhood BCP-ALL xenografts

Project description:Primary xenografts were made from a variety of different high-risk childhood BCP-ALL leukemia samples.

2015-03-05 | GSE58290 | GEO